ERGO: a pilot study of ketogenic diet in recurrent glioblastoma > 2014

본문 바로가기

접속자집계

오늘
1,615
전체
2,137,809
TEL:02-3789-7891
사이트 내 전체검색

Home >
2014

ERGO: a pilot study of ketogenic diet in recurrent glioblastoma

작성자 채식영양
작성일 14-01-01 00:00 | 조회 0 | 댓글 0

본문

J. Rieger, O. Bähr, GD. Maurer, E. Hattingen, K. Franz, D. Brucker, S. Walenta, U. Kämmerer, JF. Coy, M. Weller, et al. (2014). ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. International journal of oncology, 44(6), 1843-52. https://doi.org/10.3892/ijo.2014.2382

PubMed 24728273


[Abstract]
Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15%) discontinued the diet for poor tolerability. No serious adverse events attributed to the diet were observed. Urine ketosis was achieved at least once in 12 of 13 (92%) evaluable patients. One patient achieved a minor response and two patients had stable disease after 6 weeks. Median PFS of all patients was 5 (range, 3-13) weeks, median survival from enrollment was 32 weeks. The trial allowed to continue the diet beyond progression. Six of 7 (86%) patients treated with bevacizumab and diet experienced an objective response, and median PFS on bevacizumab was 20.1 (range, 12-124) weeks, for a PFS at 6 months of 43%. In the mouse glioma model, ketogenic diet alone had no effect on median survival, but increased that of bevacizumab-treated mice from 52 to 58 days (p<0.05). In conclusion, a ketogenic diet is feasible and safe but probably has no significant clinical activity when used as single agent in recurrent glioma. Further clinical trials are necessary to clarify whether calorie restriction or the combination with other therapeutic modalities, such as radiotherapy or anti-angiogenic treatments, could enhance the efficacy of the ketogenic diet.

0
  • 페이스북으로 보내기
  • 트위터로 보내기
  • 구글플러스로 보내기

댓글목록 0

등록된 댓글이 없습니다.

Total 125
2014 목록
번호 제목 글쓴이 날짜 조회 추천
110 텍스트 Mitochondrial encephalopathy with lactic acidosis and stroke… 링크 채식영양 01-01 0 0
109 텍스트 Combinatorial treatment of acute spinal cord injury with ghr… 링크 채식영양 01-01 0 0
108 텍스트 The effects of high fat, low carbohydrate and low fat, high … 링크 채식영양 01-01 0 0
107 텍스트 Risk of seizure recurrence after achieving initial seizure f… 링크 채식영양 01-01 0 0
106 텍스트 [The effects of a very low carbohydrate diet intervention on… 링크 채식영양 01-01 0 0
105 텍스트 Ketogenic diet in adolescents and adults with epilepsy 링크 채식영양 01-01 0 0
104 텍스트 In vivo ketogenic diet treatment attenuates pathologic sharp… 링크 채식영양 01-01 0 0
103 텍스트 Effects of ketogenic diet on vascular function 링크 채식영양 01-01 0 0
102 텍스트 Prepregnancy low-carbohydrate dietary pattern and risk of ge… 링크 채식영양 01-01 0 0
101 텍스트 A randomized pilot trial of a moderate carbohydrate diet com… 링크 채식영양 01-01 0 0
열람중 텍스트 ERGO: a pilot study of ketogenic diet in recurrent glioblast… 링크 채식영양 01-01 1 0
99 텍스트 Ketogenic diet therapy is effective in encephalitis with ref… 링크 채식영양 01-01 0 0
98 텍스트 Construction of dextrin and isomaltose-assimilating brewer's… 링크 채식영양 01-01 0 0
97 텍스트 High fat, low carbohydrate diet limit fear and aggression in… 링크 채식영양 01-01 1 0
96 텍스트 Long-term impact of the ketogenic diet on growth and resting… 링크 채식영양 01-01 1 0
게시물 검색

한국채식정보. 대표:이광조ㅣsoypaper@hanmail.netㅣ대표전화: 02-3789-7891ㅣ서울시 용산구 갈월동 56-5. 일심빌딩 203호